

Title (en)
BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES

Title (de)
BIOKONJUGATE VON SYNTHETISCHEN APELINPOLYPEPTIDEN

Title (fr)
BIOCONJUGUÉS DE POLYPEPTIDES D'APELINE SYNTHÉTIQUES

Publication
EP 3024492 A2 20160601 (EN)

Application
EP 14747491 A 20140721

Priority
• US 201361858303 P 20130725
• US 201462015848 P 20140623
• US 2014047378 W 20140721

Abstract (en)
[origin: US2015030594A1] The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I' (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

IPC 8 full level
A61K 47/48 (2006.01)

CPC (source: EP US)
A61K 38/10 (2013.01 - US); **A61K 45/06** (2013.01 - EP US); **A61K 47/542** (2017.07 - EP US); **A61K 47/643** (2017.07 - EP US); **A61K 47/68** (2017.07 - EP US); **A61K 47/6811** (2017.07 - EP US); **A61P 3/04** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 7/00** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/04** (2017.12 - EP); **A61P 9/06** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **A61P 17/02** (2017.12 - EP); **A61P 17/16** (2017.12 - EP); **A61P 21/02** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 14/47** (2013.01 - EP US); **C07K 14/765** (2013.01 - EP US); **A61K 38/00** (2013.01 - EP US); **C07K 23/30** (2013.01 - EP US); **C07K 23/31** (2013.01 - EP US)

Citation (search report)
See references of WO 2015013169A2

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
US 2015030594 A1 20150129; US 9340582 B2 20160517; AP 2016009019 A0 20160229; AU 2014293387 A1 20160211; AU 2014293387 B2 20170420; BR 112016001376 A2 20171024; CA 2918077 A1 20150129; CL 2016000157 A1 20160708; CN 105705167 A 20160622; CR 20160049 A 20160617; CU 20160012 A7 20160831; EA 201690282 A1 20160930; EP 3024492 A2 20160601; HK 1218252 A1 20170210; IL 243691 A0 20160421; JP 2016527249 A 20160908; KR 20160031552 A 20160322; MX 2016001021 A 20160803; PE 20160991 A1 20161015; PH 12016500103 A1 20160418; SG 11201600208R A 20160226; TW 201518323 A 20150516; US 2016166634 A1 20160616; UY 35671 A 20150227; WO 2015013169 A2 20150129; WO 2015013169 A3 20150319; WO 2015013169 A9 20161020

DOCDB simple family (application)
US 201414336290 A 20140721; AP 2016009019 A 20140721; AU 2014293387 A 20140721; BR 112016001376 A 20140721; CA 2918077 A 20140721; CL 2016000157 A 20160121; CN 201480052603 A 20140721; CR 20160049 A 20160125; CU 20160012 A 20160125; EA 201690282 A 20140721; EP 14747491 A 20140721; HK 16106225 A 20160601; IL 24369116 A 20160119; JP 2016529808 A 20140721; KR 20167004513 A 20140721; MX 2016001021 A 20140721; PE 2016000097 A 20140721; PH 12016500103 A 20160115; SG 11201600208R A 20140721; TW 103124997 A 20140721; US 2014047378 W 20140721; US 201615053316 A 20160225; UY 35671 A 20140721